Check out these recent Value Initiative highlights and accomplishments:

Value Initiative: 2022 Fall Update

		2022 Fall Update: Aligned Domain Goals Drive Progress Nuclear medicine is undergoing a renaissance, as evidenced by the steady introduction and approval of new radiopharmaceuticals, theranostics, and instrumentation. SNMMI's new strategic plan reflects this revitalization, and outlines our plan to continue enhancing the practice of nuclear medicine by providing professionals with the resources needed to deliver high-quality care. November 2022 Presentation

Value Initiative: 2022 Spring Update

		2022 Annual Meeting Update The launch of the Mars Shot, the new Therapy Clinical Trials Network, MIP quality measure development, a PR/media ramps up, new pipeline working groups, roadshows once again hit the road, increasing visibility on Capitol Hill, supporting the Technologists, and more! June 2022 Presentation

Value Initiative: 2021 Fall Update

		Looking Toward 2022 and Beyond New AUCs and Procedure Standards, the launch of the Mars Shot, an accreditation program for Radiopharmaceutical Therapy Centers of Excellence, upcoming summits on artificial intelligence and patient barriers, a new PR campaign to elevate nuclear medicine, increased visibility with federal legislators, and more. 2021-2022 Priorities

Value Initiative: 2021 Summer Update

		2021 Continues with Great Advocacy Efforts and Return to In-Person Events The Radiopharmaceutical Therapy Registry (RaPTR) project kick-off, introduction of the FIND Act (H.R. 4479), outreach sessions at upcoming meetings, and the return of in-person learning with the SNMMI 2021 Therapeutics Conference, (now March 10-12, 2022) in New Orleans highlight recent accomplishments. July 2021 Presentation   | 2021 Summer Updates

Value Initiative: 2021 Winter Update

		2021 Begins with Exciting Progress The launch of the dedicated Radiopharmaceutical Therapy Central website, Dosimetry Challenge, and positive news on Coverage of Non-Oncologic PET highlight early 2021 efforts. March 2021 Presentation  | 2021 Winter Updates

Value Initiative: Fall 2020 Updates and 2021 Outlook

		Targeting 2021 With a continued focus on Value Initiative 2.0, key strategic initiatives for 2021 are highlighted in this brief update. Targeting 2021 Presentation | 2020 Fall Updates

Value Initiative: 2020 Highlights

		2020 Value Initiative Highlights As we transition to Value Initiative 2.0, this comprehensive update tracks the progress and success across domains, and lays the groundwork for the exciting initiatives to come! View 2020 Progress.

Research and Discovery: SNMMI/NCI Third Targeted Radionuclide Therapy Conference 2019

		SNMMI/NCI Third Targeted Radionuclide Therapy Conference 2019 On December 16, 2019, the SNMMI and NCI co-hosted the Third Targeted Radionuclide Therapy Conference on the NCI Shady Grove campus. The theme of the meeting was: What is the Goal of Radionuclide Therapies: Palliative, Curative, or Adjuvant Treatment? Thirty-one speakers and panelists representing 3 continents, government agencies, academia, and industry informed the discussion and debate as we move forward in this promising area of medicine.  Read the news release. | View presentations from the conference.

Value Initiative: 2019 Highlights

Value Initiative: Advocacy

President Vasken Dilizian, MD, Senator Ben Cardin, Sukhjeet Ahuja MD, MS, Ira Goldman (Lantheus), and Rosemary Cioti (FORCE) meet to discuss H.R. 3772.		SNMMI Members Talk Nuclear Medicine at Congressional Policy Briefing on Capitol Hill On July 17, SNMMI co-hosted a briefing on Capitol Hill with clinicians, patients, and industry representatives to discuss the importance of nuclear medicine, diagnostic radiopharmacuticals, and specifically, H.R. 3772, also known as the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. The bill calls for all diagnostic radiopharmaceuticals that reach a cost of more than $500 per day to be paid separately in the Hospital Outpatient Perspective Payment System. Read the full release.

Value Initiative: Concept to Commercialization

		Concept to Commercialization Dedicated session for small and emerging technology companies. At the recent SNMMI Annual Meeting, experts from industry and venture capital organizations convened for a special session on facilitating a healthy molecular imaging and therapy ecosystem to grow innovative ideas into successful products that benefit patients. Core challenges specific to small and emerging technology companies, and ways to foster cross-sector partnerships were also addressed.

Value Initiative: Progress Report

		SNMMI's Value Initiative: A Progress Report  In June 2019 at the SNMMI Annual Meeting in Anaheim, the Value Initiative Industry Alliance members met to review the latest progress, initiatives and future goals of the Value Initiative. View the Progress Report to learn more about the great work SNMMI is doing to further this vision. View the Progress Report. View the Presentation.

Domain Two: Research and Discovery

Domain Two: Research and Discovery

		Theranostics Consensus Conference 2018 On November 8-9, SNMMI and the National Cancer Institute (NCI) hosted the Theranostics Consensus Conference 2018, sponsored by Progenics Pharmaceuticals. Attendees representing the major stakeholders in theranostics, including the FDA, NCI, academicians, clinical physicians, and pharmaceutical company executives gathered at the National Institutes of Health campus in Bethesda, Maryland, for two days of in-depth discussions. The conference focused on key elements within this evolving field of nuclear medicine, including the current state of theranostic technology and challenges in trial design, as well as training and requirements needed for administration and dose planning.  View Theranostics Conference presentation slides - November 8 View Theranostics Conference presentation slides - November 9

		SNMMI's Value Initiative: A Progress Report Through its Value Initiative, SNMMI is providing the strategic vision and roadmap to elevate nuclear medicine and molecular imaging, increasing its value to the medical community, regulators, patients and the public. Learn more about the great work SNMMI is doing to further this vision.

Domain Three: Workforce Pipeline and Life-Long Learning

		SNMMI Launches New Resident and Medical Student Website This new site will help showcase the field as appealing to residents, and to promote awareness among medical students exploring future specialties. Its sleek design will provide clear, concise resources, news, and requested information to three main audience segments: medical students interested in the specialty, nuclear medicine and/or radiology residents, and program directors.
Coming Soon! SNMMI will continue to enhance this new site, including working to provide Program Director resources through this site, and it is currently a forum to share feedback on what tools you’d like to see from the Society.

Domain Five: Outreach

		SNMMI’s Patient Advocacy Advisory Board Visits Capitol Hill On March 14, members of SNMMI’s Patient Advocacy Advisory Board visited the Capitol Hill offices of 15 senators, 16 representatives, and two congressional committees to educate our legislators on the need for reformed coverage of diagnostic radiopharmaceuticals
		New Video Educates Patients on DaT SPECT The SNMMI Brain Imaging Outreach Working Group’s “What to Expect” video for DaT SPECT offers a step-by-step guide to patients. The video received more than 3,000 views in its first month online.
		Roadshows Spread the Word about Diagnosing and Treating NETs The SNMMI Targeted Radioisotope Therapy Outreach Working Group has educated more than 300 physicians, techs, and patients on new developments in diagnosing and treating neuroendocrine tumors through its roadshow, which has traveled to Seattle, Salt Lake City, Phoenix, Dallas, and Washington, D.C. Next stops: Chicago, Portland, and Albuquerque.